-

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients. This agreement will leverage Invenra’s cutting-edge B-Body® bispecific antibody platform to support Astellas’ focused research and development initiatives.

Under the agreement, Astellas will have access to Invenra’s B-Body technology, marking a thoughtful step toward advancing their bispecific therapeutic research. At the conclusion of the research, Astellas will have the option to negotiate future licenses.

Dr. Roland Green, CEO of Invenra, remarks, “We are honored to partner with the Astellas team, one of the world’s foremost developers of therapeutics. We are excited by the potential of this partnership to yield profound benefits to patients in need.”

Both companies share a commitment to advancing healthcare through dedicated scientific research, aiming to bring effective and innovative treatments to patients globally.

About Invenra Inc:

Driven by our mission to deliver groundbreaking therapies to patients worldwide and a commitment to innovation and excellence, Invenra is a leading bispecific antibody technology company. Our proprietary B-Body® platform offers profound advantages in discovery, manufacturing, and formulation, along with true "Plug & Play" performance, enabling rapid engineering of therapeutics. Our extensive portfolio of wholly owned and partnered molecules includes first and best-in-class bispecifics, making us a pioneer in therapeutic innovation.

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

Industry:

Invenra Inc.

Release Versions
English

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

More News From Invenra Inc.

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a...

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (...

Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs. Building on the success of Invenra’s B-Body® bispecific platform, the T-Body platform expands the company’s capabi...
Back to Newsroom